← Eichor
Condition: Recurrent Follicular Lymphoma Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Recurrent Follicular Lymphoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Deep Phenotyping for Clinical Inferring Response in Treatment Resistant Depression
Phase N/A · 1 location(s) · Max-Planck-Institute of Psychiatry · NCT06396312huCART19-IL18-eDHFR Cells in Relapsed/Refractory Follicular Lymphoma
Phase 1 · 1 location(s) · University of Pennsylvania · NCT07343934Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
Phase 2 · 104 location(s) · SWOG Cancer Research Network · NCT05890352Chronic CED of TPT for Recurrent Malignant Glioma
Phase 1 · 1 location(s) · Jeffrey N. Bruce · NCT06666712Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies
Phase 1 · 9 location(s) · Exscientia AI Ltd., a wholly owned subsidiary of Recursion P · NCT06980116B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide
Phase 1 · 1 location(s) · Mayo Clinic · NCT06191887A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
Phase 1 · 9 location(s) · Accutar Biotechnology Inc · NCT05780034Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Phase 1/Phase 2 · 34 location(s) · Lyell Immunopharma, Inc. · NCT05826535Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Tri
Phase 2 · 1 location(s) · University of Washington · NCT06948786AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
Phase 1 · 1 location(s) · Stanford University · NCT06340737Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
Phase 2 · 1 location(s) · University of California, Davis · NCT04587687A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcita
Phase 2 · 53 location(s) · Hoffmann-La Roche · NCT06806033Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL
Phase 2 · 1 location(s) · New York Medical College · NCT02393157A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Gliobl
Phase 1 · 2 location(s) · University of Florida · NCT04573140Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T
Phase 2 · 1 location(s) · University of Washington · NCT06784726NEO100 and High-Grade Meningioma
Phase 2 · 5 location(s) · Neonc Technologies, Inc. · NCT05023018Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
Phase 2 · 94 location(s) · AstraZeneca · NCT06526793A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients
Phase 1 · 16 location(s) · OncoNano Medicine, Inc. · NCT06022029Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relap
Phase 2 · 1 location(s) · Australasian Leukaemia and Lymphoma Group · NCT06287398Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Expo
Phase 2 · 1 location(s) · City of Hope Medical Center · NCT07042438Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
Phase 1/Phase 2 · 2 location(s) · Yazeed Sawalha · NCT065360493'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Phase N/A · 1 location(s) · Barbara Ann Karmanos Cancer Institute · NCT00935090Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
Phase 1 · 7 location(s) · AIDS Malignancy Consortium · NCT05077527ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma
Phase 1/Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT07098364Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astr
Phase 1 · 43 location(s) · National Cancer Institute (NCI) · NCT06860594Registry of Older Patients With Cancer
Phase N/A · 7 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT01137825Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(
Phase 2 · 3 location(s) · Sun Yat-sen University · NCT04989621A Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Ref
Phase 1 · 1 location(s) · GenomeFrontier Therapeutics TW Co., Ltd. · NCT06703892Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT07410494Q702 for the Treatment of Patients With Hematologic Malignancies
Phase 1 · 2 location(s) · Mayo Clinic · NCT06712810
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.